Yersinia Pestis Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Yersinia Pestis Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Description:

The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsight’s report also highlights the patent, patent exclusivity information and competitive landscape. – PowerPoint PPT presentation

Number of Views:25

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Yersinia Pestis Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015


1
Yersinia Pestis Infections-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015
2
Summary
Yersinia Pestis Infections-API Insights,
2015,report provides Yersinia Pestis Infections
drugs marketed details and API Manufacturers
details across the globe along with the location.
The report gives the clear idea on the United
States Drug Master File (USDMF) and Europe DMF
filed by worldwide countries related to the drugs
falling under Yersinia Pestis Infections. The
Report provides the India and China API
Manufactures who are driving the current API
Market. DelveInsights report also highlights the
patent, patent exclusivity information and
competitive landscape. The research analysis
also presents the global sales forecasts data for
the Yersinia Pestis Infections drugs till 2016.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
3
The active pharmaceutical ingredients worldwide
market is in continuous development from the
recent years. There is expected to be a major
impact on the global API industry, with the large
number of blockbuster drugs going off patent in
the coming years. It is going to affect the
revenue of the API market as generic drugs occupy
the market. India and China produce a large
percentage of a majority of the APIs and
intermediates produced in the world currently.
The USFDA and EMA have strict guidelines for API
manufacturing 'Process Validation General
Principles and Practices'. While countries such
as Japan and Singapore are signatories to the ICH
Q7 regulation, India and China follow their
national GMP guidelines. The efficiency and
expertise of Asian contract manufacturers have
positioned them in a very strategic space in the
global pharmaceutical supply chain, with a vast
majority of the APIs and intermediates being
sourced from markets such as India and China.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
4
Data SourcesThe report is built using data and
information sourced from proprietary databases,
primary and secondary research and in-house
analysis by DelveInsight team of industry
experts. Secondary sources information and data
has been collected from various printable and
non-printable sources like search engines, News
websites, Government Websites, Trade Journals,
White papers, Magazines, Trade associations,
Books, Industry Portals, Industry Associations
and access to available databases.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
5
Scope A snapshot of the global Market
therapeutics scenario for Yersinia Pestis
Infections. A review of the marketed products
under prescription for Yersinia Pestis
Infections, regulatory information and marketing
status. Coverage of global patent coverage and
detailed commentaries on the US patent
challenges.  Graphical representation of
investigational products for patent expiry and
market exclusivities across the globe. Product
profiles for marketed products for Yersinia
Pestis Infections with complete description of
mechanism of action, therapeutic class, target,
route(s) of administration and chemical
details. Coverage of API Manufacturers for
Yersinia Pestis Infections drugs in the United
States, Europe and Asian Regions with location
details. Coverage of Regulatory filings in the
US, Europe, and Asia specifically India and China
for Yersinia Pestis Infections drugs. Key
discontinued Marketed products. Global Sales
Figure from 2012-2016.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
6
Reasons to Buy Evaluate the marketing status
and exclusivity details of Yersinia Pestis
Infections key products to exploit opportunities
for generic drug development opportunities. Key
players in the pharmaceutical industry.Strategic
drivers and restraints of this market are
revealed and market opportunities and challenges
are identified. Design effective
counter-strategies to gain competitive advantage
by identifying the key patent expiry details and
exclusivity with respect to Yersinia Pestis
Infections. API intelligence over marketed
drugs for Yersinia Pestis Infections and gaining
primary intelligence over active ingredients
manufacturers across the globe. Uncovering
opportunities in the rapidly growing the US
markets.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
7
Table of Contents
  1. Introduction Report Scope Methodology
  2. Executive Overview of Major Findings
  3. Nature Structure of the Worksite Weight Loss
    Market
  4. The National Cost of Obesity
  5. Status of the Overall U.S. Weight Loss Market
  6. Market Size Growth
  7. Competitor Profiles The Major Providers
  8. Reference Directory of Weight Loss Market
    Information Sources

W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
8
To view the full Executive Summary and Table of
Contents, please visit Yersinia Pestis
Infections-Global API Manufacturers, Marketed and
Phase III Drugs Landscape, 2015 Contact Us-Call
India 91-22-27810772/73Email id
info_at_bharatbook.com Website www.bharatbook.com
Our Blog https//www.bharatbook.com/blog/

Follow Us On
About PowerShow.com